On Thursday, Shares of Kinder Morgan Inc (NYSE:KMI), lost -2.58% to $32.72.
Kinder Morgan Inc, declared it has begun to receive Powder River Basin volumes into its Double H pipeline system via a newly constructed connection near Douglas, Wyoming, for crude oil deliveries to Guernsey, Wyoming, increasing its system capacity to about 99,000 barrels per day (bpd). The Powder River Basin project is the result of the successful open season held earlier this year on the local Double H pipeline and the joint Hiland/Pony Express systems which resulted in additional commitments to the Double H pipeline from sources in North Dakota and Wyoming.
Kinder Morgan’s Double H pipeline is supplied by the Market Center Gathering system in the Bakken and terminates near Guernsey. The 485-mile pipeline transports crude oil from the Dore Terminal in North Dakota and the Albin Terminal in Montana to Guernsey. At Guernsey, Double H anticipates placing delivery connections to the Plains All American Pipeline, Guernsey Station and Sinclair Guernsey Terminal into service in the third quarter of 2015 to provide raised connectivity to local and regional markets. Shippers also have access via an interconnect with the Pony Express Pipeline for transportation to the Phillips 66 Refinery in Ponca City, Oklahoma, or the Deeprock Terminal in Cushing, Oklahoma. Double H was placed in service in February 2015.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
Finally, Mylan NV (NASDAQ:MYL), ended its last trade with -3.74% loss, and closed at $53.03.
Mylan NV, commented on a warning letter issued by the U.S. Food and Drug Administration (FDA) on Aug. 6, 2015, regardingits Agila Specialty Formulation Facility (SFF), Sterile Product Division (SPD), and Onco Therapies Limited (OTL) sites in India. This action follows inspections of the three sites by FDA as much as a year ago, in 2014 and February 2015, which Mylan has revealed formerly.
Mylan CEO Heather Bresch commented, “Since Mylan attained the Agila injectables businesses in December 2013 to create a leading global injectables platform, we have been taking extensive action to integrate the Agila business into Mylan’s One Quality Standard, and to ensure our leading position as a high quality, reliable source of injectables for the long term. As part of this ongoing process, we have a deep and unwavering commitment to quality everywhere we operate. We have been and will continue to work diligently to address all of the FDA’s observations and have made important progress.”
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
